I-Mab Reports Promising Results From Phase 1 Study Of Givastomig In Gastric Cancer
17/9 04:55
(RTTNews) - I-Mab (IMAB) said that an expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, demonstrated promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and...